Altimmune Investors Urged to Act as Class Action Deadline Looms

Altimmune Investors Urged to Act as Class Action Deadline Looms

2025-09-12 companies

New York, Saturday, 13 September 2025.
Rosen Law Firm advises Altimmune investors to seek legal counsel before October 6, 2025, due to potential losses linked to misleading trial results.

Background on the Class Action Lawsuit

The Rosen Law Firm, a global investor rights entity, has initiated a securities class action lawsuit against Altimmune, Inc. (NASDAQ: ALT). The lawsuit addresses claims of securities fraud linked to Altimmune’s IMPACT Phase 2b MASH trial, specifically regarding the alleged misrepresentation of trial data. The Class Period specified for this action spans from August 10, 2023, to June 25, 2025, during which investors are believed to have suffered financial losses due to misleading information about the trial’s outcomes [1][2].

Allegations and Investor Impacts

According to the lawsuit, Altimmune is accused of creating a false impression about the reliability of the IMPACT Phase 2b MASH trial results. The trial failed to meet its primary endpoint of statistical significance for fibrosis reduction, yet Altimmune allegedly concealed higher placebo group responses, which negatively affected the topline results. Consequently, when the true details were revealed, the stock price reportedly dropped significantly, impacting investor sentiment and financial stability [1][3][4].

Investors affected by these developments are encouraged to secure legal counsel before the lead plaintiff deadline of October 6, 2025. The Rosen Law Firm has emphasized the importance of selecting experienced counsel for such class actions. Notably, the firm has a history of successfully litigating significant securities class actions and is currently offering to represent affected investors on a contingency fee basis, eliminating out-of-pocket costs [1][2][5].

Future Implications for Altimmune Investors

The outcome of this legal action could have substantial implications for Altimmune, Inc. and its investors. With the class action lawsuit in progress, investors are advised to remain vigilant and informed about their legal rights and the potential for financial recovery. The situation serves as a critical reminder of the importance of transparency and accountability in the biopharmaceutical sector, where trial data can significantly influence market perceptions and investment decisions [1][3][5].

Sources


class action Altimmune